GlassScriptPhysician profile
Murray I Wellner
NPI 1508887290
$63,186.27
in general payments reported to CMS, 2019-2025
86 companies · $9,419 in 2025
The $9,419 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $6,006 · 2021: $9,286 · 2022: $8,821 · 2023: $9,287 · 2024: $9,204 · 2025: $9,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27K · Education: $283 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27,452.16 |
| Education | $283.18 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,942.70 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $6,716.79 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $3,868.00 | 2019-2025 | Repatha, Prolia, Tezspire |
| Lilly USA, LLC | $2,950.99 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $2,830.50 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $2,694.57 | 2019-2025 | Spravato, Invega Sustenna |
| Novo Nordisk INC | $2,471.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,233.85 | 2019-2025 | Jardiance, Synjardy |
| Arbor Pharmaceuticals, INC. | $2,211.67 | 2019-2022 | |
| Antares Pharma, INC. | $1,679.89 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Biocryst US Sales Co., LLC | $1,491.98 | 2023-2025 | Orladeyo |
| Amarin Pharma, INC. | $1,413.45 | 2019-2023 | |
| Abbott Laboratories | $1,208.95 | 2019-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,197.37 | 2019-2025 | Xifaxan |
| Pfizer INC. | $1,178.86 | 2019-2025 |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,147.32 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,145.24 | 2022-2025 | |
| Esperion Therapeutics, INC. | $1,143.66 | 2020-2025 | Nexletol, Nexlizet |
| Novartis Pharmaceuticals Corporation | $1,093.55 | 2019-2025 | |
| Horizon Therapeutics Plc | $992.63 | 2019-2023 | Tepezza |
| Allergan, INC. | $918.52 | 2019-2020 | |
| Optinose US, INC. | $828.11 | 2019-2025 | |
| Azurity Pharmaceuticals, INC. | $820.61 | 2023-2025 | Horizant, Horizant, Edarbi |
| Kowa Pharmaceuticals America, INC. | $811.93 | 2019-2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $796.93 | 2021-2025 | Caplyta |
| Eisai INC. | $791.69 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $673.88 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $671.08 | 2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $500.02 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $479.42 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $444.36 | 2022-2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $431.11 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $401.45 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $387.26 | 2019-2024 | Dupixent |
| Corium, LLC | $361.41 | 2022-2025 | Azstarys |
| Astellas Pharma US INC | $340.39 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $319.59 | 2019-2024 | Trintellix |
| Scilex Pharmaceuticals INC. | $294.34 | 2019-2024 | |
| Shire North American Group INC | $280.88 | 2019 | |
| Exact Sciences Corporation | $252.15 | 2023-2025 | Cologuard Collection Kit |
| Halozyme INC | $247.63 | 2023 | |
| Ardelyx, INC. | $209.86 | 2024-2025 | Ibsrela |
| Lundbeck LLC | $207.15 | 2024-2025 | Rexulti |
| Indivior INC. | $199.21 | 2019-2023 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $191.30 | 2024-2025 | Rexulti |
| Evoke Pharma, INC. | $191.18 | 2024-2025 | |
| Corcept Therapeutics | $189.91 | 2020 | |
| Ironshore Pharmaceuticals INC. | $185.80 | 2019-2024 | |
| Verona Pharma, INC. | $183.50 | 2025 | Ohtuvayre |
| Neos Therapeutics, LP | $168.56 | 2019-2022 | |
| Qol Medical, LLC | $164.27 | 2021-2022 | |
| Almatica Pharma LLC | $157.01 | 2021-2024 | Loreev Xr, Gralise, Teriparatide |
| Alkermes, INC. | $148.66 | 2025 | Lybalvi, Aristada |
| Tris Pharma INC | $148.66 | 2023-2025 | Dyanavel Xr |
| Mdd US Operations, LLC | $146.54 | 2019 | |
| Aytu Biopharma, INC. | $141.17 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $140.44 | 2019-2024 | Linzess |
| Vertical Pharmaceuticals, LLC | $128.87 | 2024-2025 | Relexxii |
| Sunovion Pharmaceuticals INC. | $124.84 | 2019 | |
| Adlon Therapeutics L.P. | $123.78 | 2020-2021 | |
| Boston Scientific Corporation | $117.04 | 2022-2023 | Watchman |
| E.R. Squibb & Sons, L.L.C. | $115.27 | 2021-2023 | Eliquis |
| Intra-Sana Laboratories | $108.87 | 2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Bausch Health US, LLC | $108.61 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $102.93 | 2021 | |
| Orexo US, INC. | $102.48 | 2019-2024 | Zubsolv |
| Currax Pharmaceuticals LLC | $93.35 | 2020-2022 | |
| Janssen Biotech, INC. | $76.11 | 2019 | |
| Endo Pharmaceuticals INC. | $63.81 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $63.22 | 2022 | |
| Circassia INC. | $56.01 | 2019 | |
| Neurocrine Biosciences, INC. | $47.85 | 2021 | |
| Dexcom, INC. | $37.83 | 2023 | Dexcom G6 Transmitter |
| Actelion Pharmaceuticals US, INC. | $34.43 | 2024 | Opsumit, Uptravi |
| Nabriva Therapeutics, Plc | $33.24 | 2021 | |
| Supernus Pharmaceuticals, INC. | $24.18 | 2023 | Xyosted, Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $23.11 | 2022 | |
| Integra Lifesciences Corporation | $21.27 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Sumitomo Pharma America, INC. | $19.57 | 2024 | Gemtesa |
| Fidia Pharma USA INC. | $19.29 | 2023 | Hymovis, Triluron |
| Metuchen Pharmaceuticals | $18.66 | 2020 | |
| Tersera Therapeutics LLC | $18.49 | 2019 | |
| Cequr Corporation | $18.10 | 2023 | Cequr Simplicity |
| Kaleo, INC. | $18.02 | 2019 | |
| Genzyme Corporation | $14.29 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$150.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murray Wellner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.